Diabetes mellitus disrupts wound repair and leads to the development of chronic wounds, likely due to impaired angiogenesis. We previously demonstrated that human proinsulin C-peptide can protect against vasculopathy in diabetes; however, its role in impaired wound healing in diabetes has not been studied. We investigated the potential roles of C-peptide in protecting against impaired wound healing by inducing angiogenesis using streptozotocin-induced diabetic mice and human umbilical vein endothelial cells. Diabetes delayed wound healing in mouse skin, and C-peptide supplement using osmotic pumps significantly increased the rate of skin wound closure in diabetic mice. Furthermore, C-peptide induced endothelial cell migration and tube formation in dose-dependent manners, with maximal effect at 0.5 nM. These effects were mediated through activation of extracellular signal-regulated kinase 1/2 and Akt, as well as nitric oxide formation. C-peptide-enhanced angiogenesis in vivo was demonstrated by immunohistochemistry and Matrigel plug assays. Our findings highlight an angiogenic role of C-peptide and its ability to protect against impaired wound healing, which may have significant implications in reparative and therapeutic angiogenesis in diabetes. Thus, C-peptide replacement is a promising therapy for impaired angiogenesis and delayed wound healing in diabetes.
INTRODUCTION
Human proinsulin C-peptide is secreted into circulation in equimolar concentrations with insulin by pancreatic b-cells (Ido et al., 1997; Wahren et al., 2007; Hills et al., 2010; Wahren et al., 2012) . C-peptide prevents diabetic complications, including neuropathy, nephropathy, vascular dysfunctions, and inflammation, in animal models of diabetes and in type 1 diabetes mellitus (DM) patients (Ido et al., 1997; Wahren et al., 2007; Hills et al., 2010; Wahren et al., 2012) . In diabetes, increased intracellular reactive oxygen species levels are recognized as the most common cause of diabetic vascular complications (Giacco and Brownlee, 2010) . We previously demonstrated that C-peptide can ameliorate endothelial dysfunction through inhibiting intracellular reactive oxygen species-mediated apoptosis of endothelial cells by activating AMP-activated protein kinase a (Bhatt et al., 2013a,b) . Recently, we also demonstrated the protective role of C-peptide against diabetic retinopathy by amelioration of retinal microvascular leakage (Lim et al., 2013) . The multifaceted effects of C-peptide in diabetic animals and in patients are attributed to the activation of multiple cell signaling pathways, involving p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 (ERK1/2), Akt, and endothelial nitric oxide (NO) production (Kitamura et al., 2002; Wallerath et al., 2003; Zhong et al., 2005) . However, the mechanism(s) by which C-peptide prevents and/or ameliorates diabetic complications is not fully understood.
C-peptide deficiency is a typical feature of type 1 DM and the later stages of type 2 DM (Wahren et al., 2007; Massi-Benedetti and Orsini-Federici, 2008) . DM is one of the major contributors of impaired wound healing; it leads to apoptosis and abnormal angiogenesis (Hansen et al., 2003; Graves et al., 2007) . Impaired wound healing can result in diabetic complications, including chronic open wounds, infections, and ulcers, and even amputation (Ferringer and Miller, 2002; Jeffcoate and Harding, 2003; Hirsch et al., 2008) . Wound healing is a dynamic and interactive process involving angiogenesis, coagulation, inflammation, tissue formation, and tissue remodeling controlled by growth factors (Li et al., 2007; Monroe and Hoffman, 2012; Newman and Hughes, 2012) . Angiogenesis, the formation of new blood vessels from preexisting vessels, is a crucial process for wound healing (Sun et al., 2011) . Therefore, understanding the mechanism(s) involved in the prevention of impaired wound healing is necessary to ameliorate diabetic complications (Eming et al., 2007; Kolluru et al., 2012) . C-peptide treatment has been implicated in the prevention of diabetes complications. However, the beneficial role of C-peptide in preventing against impaired wound healing and angiogenesis due to diabetes is not clear.
In the present study, we aimed to elucidate the physiological functions of C-peptide with regard to impaired wound healing in diabetes. We hypothesized that C-peptide might exert a beneficial effect on impaired wound healing by stimulating angiogenesis and inhibiting inflammation. We investigated the role of C-peptide in therapeutic angiogenesis and excisional skin wound repair using streptozotocininduced diabetic mice. We further examined the potential role of C-peptide and its underlying mechanisms in the process of vascular angiogenesis through the activation of ERK1/2, Akt, and NO production using human umbilical vein endothelial cells (HUVECs) in vitro. We assessed neovascularization using the Matrigel plug assay and immunohistochemistry. In addition, we demonstrated that C-peptide normalizes increased inflammatory cytokine levels and infiltrated inflammatory cells in diabetic mice.
RESULTS

C-peptide prevents impaired wound healing in diabetic mice
To investigate whether C-peptide could normalize impaired wound healing in diabetic mice, C-peptide was continuously supplemented using subcutaneously implanted osmotic pumps in streptozotocin-induced diabetic mice. Wounds of 4-mm diameter were created on the dorsal surface of the hindlimbs of normal, diabetic, and C-peptide-supplemented diabetic mice. Diabetic mice exhibited a significantly slower healing rate compared with normal mice (Figure 1a ). However, C-peptide supplement accelerated wound closure in diabetic mice. This effect was quantitatively analyzed by measuring wound diameter ( Figure 1b ). Wound closure was much slower in diabetic mice compared with normal mice (n ¼ 10, Po0.001); however, C-peptide supplementation attenuated this effect (n ¼ 10, Po0.01). To further study the C-peptide-mediated stimulation of wound closure, we analyzed hematoxylin and eosin-stained transverse sections of the wound beds (Supplementary Figure S1 online). As suggested by macroscopic observation, wound closure was dramatically stimulated by C-peptide at 10 days ( Figure 1c ). Similar results were obtained by measuring length and area of hyper-proliferative epithelium at 6 days (Figure 1d ,e). Our results indicate that C-peptide prevents against impaired wound healing including wound closure in diabetic mice.
C-peptide activation of endothelial cell migration, proliferation, and tube formation
Because angiogenesis is a crucial process for wound healing (Sun et al., 2011) , we investigated whether C-peptide could activate endothelial cell migration, proliferation, and tube formation. C-peptide treatment induced a dose-dependent increase in endothelial cell chemotactic migration, with a maximal effect at 0.5 nM (Figure 2a and b). However, heatinactivated C-peptide had no effect on endothelial cell migration (data not shown). C-peptide-induced cell migration was further investigated with wound-healing assays. C-peptide (0.5 nM) significantly stimulated cell migration to the wounded area (Po0.01, Figure 2c and d), with cell proliferation demonstrated by increase in cell viability (Po0.05, Figure 2e ). As reported previously (Caldwell et al., 2003; Lamalice et al., 2007) , vascular endothelial growth factor (VEGF) also stimulated chemotactic migration, wound healing, and proliferation in endothelial cells (Figures 1 and 2) .
Consistent with the cell migration assay results, C-peptide stimulated tube formation in a dose-dependent manner, with maximal effect at 0.5 nM (Figure 3a and b). VEGF induced similar tube formation ( Figure 3c ). Thus, it was confirmed that C-peptide activates endothelial cell migration, proliferation, and tube formation, which are essential for in vitro angiogenesis.
C-peptide stimulation of angiogenesis through pathways involving ERK1/2, PI 3 K/Akt, and NO production To understand the mechanism by which C-peptide activates angiogenesis, we investigated the effect of C-peptide on upstream pathways of angiogenesis, including ERK1/2 and Akt phosphorylation and NO production. C-peptide increased ERK1/2 phosphorylation in a time-dependent manner, with maximal stimulation at 15 minutes, and this ERK1/2 activation was maintained until 60 minutes (Figure 4a) . Similarly, C-peptide induced time-dependent Akt phosphorylation, with maximal effect at 15 minutes ( Figure 4b ). VEGF also induced ERK1/2 and Akt phosphorylation in a time-dependent manner (Figure 4a and b). Because Akt phosphorylation increases NO production via VEGF, which is an important angiogenesismediating factor (Dimmeler et al., 1999) , we investigated whether C-peptide could stimulate NO production ( Figure 4c ). Treatment of HUVECs with C-peptide significantly elevated intracellular NO (Po0.05). A higher level of intracellular NO was produced with VEGF treatment (Po0.01). These results suggest that signaling pathways involving ERK1/2, Akt, and NO production might be involved in C-peptide-induced angiogenesis.
The roles of ERK1/2, PI 3 K/Akt, and NO in C-peptideinduced angiogenesis were examined using PD98059, wortmannin, and L-NG-nitroarginine methyl ester (L-NAME), respectively ( Figure 3d ). C-peptide-stimulated tube formation of HUVECs was inhibited by PD98059, the inhibitor of ERK1/2, in a dose-dependent manner, with maximal inhibition at 10 mM. The PI 3 K/Akt inhibitor wortmannin and the NO synthase inhibitor L-NAME also dose dependently inhibited C-peptide-induced tube formation. As expected, VEGFinduced tube formation was prevented by treatment with PD98059, wortmannin, or L-NAME ( Figure 3e ). Our results indicate that C-peptide stimulates angiogenesis via signaling pathways involving ERK1/2, PI 3 K/Akt, and NO production.
C-peptide activation of blood vessel formation in diabetic mice
To investigate the effect of C-peptide on blood vessel formation in the wound, the inner surface of dorsal skins from normal, diabetic, and C-peptide-supplemented diabetic mice was photographed. Blood vessels were obvious in the subcutaneous tissue surrounding the wounds in normal mice but not in the wound of diabetic mice (Figure 5a ). Blood vessel formation was apparent in C-peptide-supplemented diabetic mice.
C-peptide-induced blood vessel formation was also investigated by confocal microscopy of the inner surface of the dorsal skins from three groups of mice after platelet endothelial cell adhesion molecule-1 (PECAM-1) staining of blood vessels (Figure 5b ). PECAM-1 immunohistochemistry revealed increased blood vessel formation in normal and C-peptidesupplemented diabetic mice compared with diabetic mice (Figure 5b and c), indicating that C-peptide activated blood vessel formation in the skin of diabetic mice. C-peptideinduced formation of blood vessels was supported by the Matrigel plug assay. One week after implantation in C57BL/6 mice, Matrigel containing C-peptide exhibited significantly greater angiogenesis compared with control, and this result was similar to that observed following VEGF treatment ( Figure 5d ). C-peptide activation of blood vessel formation was further confirmed by confocal microscopy of transverse sections of wound beds after immunohistochemistry with anti-PECAM-1 and a-smooth muscle actin antibodies (Figure 6a ). The number of blood vessels was significantly lower in diabetic mice compared with normal mice (Po0.01), and this effect was normalized in C-peptide supplementation (Figure 6a and b) , indicating that C-peptide activates neovascularization in the wound bed of diabetic mice. Thus, C-peptide normalizes impaired wound healing by activating angiogenesis in diabetic mice.
C-peptide inhibition of inflammation in diabetic mice
To investigate C-peptide effect on inflammation in the wounds, we performed immunohistochemistry on transverse sections of wound beds from normal (10 days), diabetic (20 days), and C-peptide-supplemented diabetic mice (12 days) and determined the levels of inflammatory cytokines by confocal microscopy. Diabetic mice demonstrated significantly higher levels of IL-1b, IL-6, and tumor necrosis factora (TNF-a) compared with normal mice, which were normalized by C-peptide supplementation (Po0.01; Figure 6c ), indicating that C-peptide inhibits inflammation in diabetic mice. In addition, C-peptide reversed the increased number of infiltrated inflammatory cells (CD11b-and Ly6c-positive cells) in diabetic mice (Po0.05; Figure 6d ). Taken together, our data indicate that C-peptide normalizes impaired wound healing by activating angiogenesis as well as inhibiting inflammation in diabetic mice. (c) Tube formation induced by 10 ng ml À 1 VEGF or 0.5 ng ml À 1 C-peptide. **Po0.01; VEGF or C-peptide versus control (CON). (d) Human umbilical vein endothelial cells (HUVECs) were incubated for 24-30 hours with 0.5 nM C-peptide in the presence of the indicated concentrations of PD98058 (mM), wortmannin (nM), or L-NG-nitroarginine methyl ester (L-NAME) (mM). (e) HUVECs were incubated with 10 ng ml À 1 VEGF in the presence of 10 mM PD98058, 100 nM wortmannin, or 2 mM L-NAME. Results are represented as mean±SD of three independent experiments. *Po0.05, **Po0.01; for inhibitors versus C-peptide or VEGF. angiogenic factor treatment (Werner and Grose, 2003) . Granulation tissue formation and enhanced re-epithelialization are associated with increased angiogenesis and an increase in fibroblast number (Fadini et al., 2010) . Our results demonstrate the preventive role of C-peptide against impaired wound healing through stimulating angiogenesis and inhibiting inflammation in streptozotocin-induced diabetic mice. There is a report that C-peptide had no effect on diabetic wound healing; however, this controversy might be caused by using non-physiological C-peptide concentration (over 10 nM in plasma) (Langer et al., 2002) . C-peptide replacement therapy has been investigated in animal models of diabetic neuropathy and nephropathy but not in diabetesimpaired wound healing. We systemically administered C-peptide to diabetic mice to investigate the protective role of C-peptide against diabetes-impaired wound healing. The most important finding of the present study is that C-peptidetreated diabetic mice showed significantly improved wound healing.
DISCUSSION
We further investigated the underlying mechanisms of C-peptide protection in the process of vascular angiogenesis through the activation of ERK1/2, Akt, and NO production; this effect was demonstrated in parallel with VEGF-induced angiogenesis. ERK1/2 has a distinct role in tube formation by endothelial cells and tube structure maintenance during angiogenesis, whereas NO stimulates endothelial cell proliferation and migration (Yang et al., 2004) . We demonstrated increases in endothelial cell proliferation, migration, and tube formation following C-peptide treatment, with a maximum effect observed within its physiological concentration (0.5 nM); these effects were similar to those observed following VEGF treatment. In parallel with VEGF, C-peptide also stimulated . C-peptide activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt phosphorylation and nitric oxide (NO) production in human umbilical vein endothelial cells (HUVECs). (a, b) HUVECs were treated with 10 ng ml À 1 vascular endothelial growth factor (VEGF) or 0.5 nM C-peptide for the indicated times. Phosphorylation of (a) ERK1/2 and (b) Akt was determined by western blot analyses. The levels of protein phosphorylation were normalized using the total amount of the proteins and expressed relative to unstimulated control levels (CON). (c) HUVECs were treated with 10 ng ml À 1 VEGF or 0.5 nM C-peptide for 2 hours, and levels of intracellular NO were determined by confocal microscopy as described in the Methods. Bar ¼ 100 mm. Results are expressed as mean ± SD of three independent experiments. *Po0.05, **Po0.01; for VEGF or C-peptide versus control.
ERK1/2 and Akt phosphorylation and NO production in endothelial cells. Blocking the ERK1/2, PI 3 K/Akt, or endothelial NO species pathway using specific inhibitors suppressed in vitro tube formation induced by both C-peptide and VEGF. Moreover, the in vivo Matrigel plug assay results demonstrated a significant increase in angiogenesis upon C-peptide treatment, similar to that induced by VEGF treatment. Thus, C-peptide has significant VEGF-mimetic angiogenic potency both in vitro and in vivo.
We investigated whether C-peptide-mediated acceleration of wound repair was mediated via its effect on wound site. C-peptide supplementation normalized increased levels of inflammatory cytokines and CD11b-and Ly6C-positive cells in the wound bed of diabetic mice. The normal woundhealing process is initiated by migration of keratinocytes and fibroblasts. In diabetes, increased inflammatory cytokines, such as IL-1b, IL-6, and TNF-a, induce impaired wound healing by suppressing keratinocyte and fibroblast migration (Xu et al., 2013) . C-peptide induced migration of NIH3T3 cells in vitro ( Supplementary Figure S2 online) , suggesting that C-peptide can directly activate fibroblasts for accelerating wound repair. However, C-peptide did not activate the HaCaT cell migration (data not shown), indicating that C-peptide may indirectly reverse diabetes-induced suppression of keratinocyte migration through inhibiting inflammatory cytokines. PECAM-1 immunohistochemistry demonstrated new blood Figure 5 . C-peptide activation of blood vessel formation in diabetic mice. (a, b) Dorsal skin tissues were excised from the hindlimbs of normal (n ¼ 6), diabetic (n ¼ 6), and C-peptide-supplemented diabetic (Diabetic þ C-peptide, n ¼ 6) mice at 10, 20, and 12 days after wounding, respectively, and were immediately subjected to immunohistochemistry with a platelet endothelial cell adhesion molecule-1 (PECAM-1) antibody. The inner surface of the dorsal skin from each group of mice was photographed (a), and blood vessels were observed by confocal microscopy (b). Arrows indicate vessels. Bar ¼ 200 mm.
(c) Total vessel length (mm) per field was determined using the images in b. **Po0.01. (d) In vivo the Matrigel plug assay; mice were injected subcutaneously for 7 days with 0.5 ml Matrigel containing vehicle (CON), 100 ng ml À 1 vascular endothelial growth factor (VEGF), or 5 nM C-peptide (n ¼ 8 per group).
vessel formation in the wounded dorsal skin. Blood vessels from intact vessels and loops of new capillaries gave the matrix a red granular appearance. Thus, C-peptide has a beneficial role in preventing diabetes-impaired wound healing via its effect on anti-inflammation and neovascularization.
In conclusion, our study reveals an angiogenic role of C-peptide exerted via pathways involving ERK1/2 and Akt phosphorylation and NO production. C-peptide supplement therapy improved diabetes-impaired wound healing by inhibiting inflammation and stimulating angiogenesis. Thus, C-peptide replacement is a promising therapeutic strategy for diabetes-impaired wound healing.
MATERIALS AND METHODS
Animals
Six-week-old male C57BL/6 mice were obtained from KOSTECH (Pyeongtaek, Korea). Mice were maintained in temperature-controlled clean racks with a 12-hour-light/dark cycle. All experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Ethics Committee of Kangwon National University.
Diabetic mouse model
Diabetic mice were generated by a single intraperitoneal injection of streptozotocin (150 mg per kg body weight) as previously described Figure 6 . C-peptide activation of neovascularization and inhibition of inflammation in the wound beds. Wound beds were excised from the hindlimbs at 10 days (normal, n ¼ 6), 20 days (Diabetic, n ¼ 6), and 12 days (Diabetic þ C-peptide, n ¼ 6) after wounding. Immunohistochemistry was performed using platelet endothelial cell adhesion molecule-1 (PECAM-1), a-smooth muscle actin (a-SMA), 4',6-diamidino-2-phenylindole (DAPI), CD11b, Ly6C, IL-1b, IL-6, and tumor necrosis factor-a (TNF-a) antibodies, and stained sections were observed using confocal microscopy. (Bhatt et al., 2013a) . After 1 week, mice with non-fasting blood glucose levels greater than 16 mM, polyuria, and glucosuria were defined as diabetic. Two weeks after the streptozotocin injection, one group of diabetic mice was subcutaneously implanted with ALZET mini-osmotic pumps 2004 (DIRECT, Cupertino, CA) containing C-peptide in phosphate-buffered saline with a delivery rate of 35 pmol kg À 1 per minute for 2 weeks. The other diabetic and normal groups underwent sham operations.
Skin excision wound and quantitative assessment of wound healing
The dorsal skin of the vertebral column was shaved with Veet cream before creating a wound. Full-thickness skin wounds, 4 mm in diameter, were created on the dorsal surface of the hindlimbs with a biopsy punch, and closure was monitored with a digital camera. Open-wound size was measured by tracing the wound margin using a vernier caliper every other day.
Cell culture
HUVECs were isolated from the human umbilical cord vein according to the Declaration of Helsinki as previously described (Park et al., 2009) . Cells were grown at 37 1 C in a humidified 5% CO 2 incubator in M199 culture media supplemented with 20% fetal bovine serum, 3 ng ml À 1 basic fibroblast growth factor, 5 U ml À 1 heparin, 100 U ml À 1 penicillin, and 100 mg ml À 1 streptomycin. For experiments, cells were incubated for 6 hours in low-serum medium (M199 supplemented as above), but with only 1% fetal bovine serum. Cell viability was accessed by the Cell Counting Kit-8 (Enzo Life Sciences, Farmingdale, NY).
Transwell migration assay
Migration assays were performed as previously described (Lee et al., 2006) . Briefly, HUVEC chemotactic motility was assayed using Transwell Permeable Supports (Costar, Corning, NY). The lower surface of the filters was coated with 5 ml 2% gelatin. Low-serum media containing VEGF or C-peptide were placed in the lower wells. HUVECs were seeded in the upper wells in a volume of 200 ml lowserum media containing 1 Â 10 5 cells per well and incubated at 37 1 C for 12 hours. Cells were fixed with 100% methanol for 15 minutes and then stained with hematoxylin and eosin. The average number of migrated cells in three randomly chosen fields per insert was taken to quantify the extent of migration using a fluorescence inverted microscope (Olympus, Tokyo, Japan).
Wound-healing assay
Confluent cell layers were starved with low-serum media for 6 hours, stained with 1 mM calcein-AM for 30 minutes, and wounded with a plastic scraper. Cell debris was removed and replaced with 2 ml low-serum media containing VEGF or C-peptide. Cells were then incubated at 37 1 C for 24 hours, and the number of migrated cells was counted from images obtained using a confocal microscope (FV-300, Olympus).
Tube formation assay
The formation of capillary-like networks by HUVECs on growth factor-reduced Matrigel (BD Biosciences, Franklin Lakes, NJ) was achieved as previously described (Namkoong et al., 2009 ). Briefly, 24-well culture plates were coated with Matrigel according to the manufacturer's instructions. HUVECs were seeded onto a layer of Matrigel at a density of 4 Â 10 5 cells per well and treated with VEGF or C-peptide at 37 1 C for 24-30 hours. The degree of tube formation was quantified by measuring tube length from the images using FV-300 software (Olympus).
Western blot analyses
HUVECs were scraped off with ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 10 mg ml À 1 aprotinin, and 10 mg ml À 1 leupeptin) and centrifuged at 18,000g for 10 minutes at 4 1 C. The resulting cell lysates were separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes. Protein bands were visualized using a chemiluminescent substrate (Pierce, Rockford, IL).
Measurement of intracellular NO production
Intracellular NO levels were measured using diaminofluorescein-FM diacetate (Molecular Probes, Eugene, OR) as previously described (Namkoong et al., 2009) . Briefly, HUVECs were treated with VEGF or C-peptide in phenol red-free low-serum media for the indicated times and incubated with 2 mM diaminofluorescein-FM diacetate for the final 60 minutes. Intracellular NO levels were determined by comparing the fluorescence intensities of treated cells with those of untreated control cells.
Whole-mount immunostaining
Skin tissues were excised using scissors and were immediately fixed overnight with 4% paraformaldehyde in phosphate-buffered saline. For immunohistochemistry, tissue samples were blocked with 2% BSA in tris-buffered saline containing 0.1% Triton X-100 and incubated with goat-polyclonal PECAM-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 2 days, followed by probing with Alexa 546-conjugated rabbit anti-goat IgG overnight and observed under the confocal microscope (FV-300). The length of blood vessel was determined using FV-300 software (Olympus).
In vivo Matrigel plug assay
In vivo Matrigel plug assays were performed as previously described ( Min et al., 2007) . Briefly, mice were injected subcutaneously with 0.5 ml Matrigel containing 100 ng ml À 1 VEGF or 5 nM C-peptide and 10 U heparin. After 7 days, the Matrigel plugs were removed from the subcutaneous region and photographed with a camera (Sony, Tokyo, Japan).
Histology and immunohistochemistry
Full-skin thickness samples of wound tissue from mice were excised using scissors, fixed immediately in 4% paraformaldehyde in phosphate-buffered saline for overnight, and then embedded in paraffin. In total, 8-mm paraffin skin sections were cut (Leica, Nussloch, Germany). Hematoxylin and eosin staining was performed in Harris hematoxylin solution (Sigma, St Louis, MO) for 5 minutes, followed by 0.5% eosin (Sigma) for 2 minutes. The wound diameter and hyperproliferative epithelium length and area were determined using FV-300 software (Olympus, Tokyo, Japan). Immunohistochemistry was performed using goat-polyclonal PECAM-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit-polyclonal a-smooth muscle actin and CD11b antibodies (Santa Cruz Biotechnology), rat-polyclonal Ly6C (BD Biosciences, Franklin Lakes, NJ), IL-1b, IL-6, and TNF-a antibodies (Abcam, Cambridge, MA), followed by probing with Alexa 546-conjugated rabbit anti-goat IgG, FITC-conjugated goat anti-rabbit IgG, or FITCconjugated goat anti-rat IgG for 2 hours, and stained samples were observed using confocal microscopy (FV-300). The number of blood vessel and inflammatory cells was counted and the level of inflammatory cytokines was determined from the images.
Statistical analysis
Data processing was performed using Origin 6.1 (OriginLab, Northampton, MA). Statistical significance was determined using Student's t-tests and analysis of variance. A P-value less than 0.05 was considered statistically significant.
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